Bicycle Therapeutics PLC (NASDAQ:BCYC)
| Market Cap | $202.98M-57.0% |
| Revenue (ttm) | $83.53M+194.7% |
| Net Income | -$141.79M+43.4% |
| EPS | -$2.03+43.8% |
| Shares Out | 69.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,023,517 |
| Open | $2.98 |
| Previous Close | $3.05 |
| Day's Range | $2.85 - $2.98 |
| 52-Week Range | $2.85 - $7.83 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | $10.00(+244.83%) |
| Earnings Date | Mar 16, 2027 |
About BCYC
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 16, 2027Earnings report
$BCYC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BCYC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BCYC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BCYC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BCYC Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BCYC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BCYC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BCYC
| IBBiShares Biotechnology ETF | $840.02K |
| BBCVirtus Biotech Clinical Trials ETF | $201.05K |
| SBIOALPS Medical Breakthroughs ETF | $178.12K |
| GWXState Street SPDR S&P International Small Cap ETF | $116.94K |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $89.38K |
| APIEActivePassive International Equity ETF | $59.28K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BCYC’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.67% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.51% |
| MEDX | Horizon Kinetics Medical ETF | 0.22% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.11% |
| PEPT | REX Peptide ETF | 0.08% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.01% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| APIE | ActivePassive International Equity ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.
